image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.54
8 %
$ 12 M
Market Cap
-1.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one PETV stock under the worst case scenario is HIDDEN Compared to the current market price of 0.54 USD, PetVivo Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one PETV stock under the base case scenario is HIDDEN Compared to the current market price of 0.54 USD, PetVivo Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one PETV stock under the best case scenario is HIDDEN Compared to the current market price of 0.54 USD, PetVivo Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
969 K REVENUE
5.62%
-10.6 M OPERATING INCOME
-21.62%
-11 M NET INCOME
-25.67%
-7.42 M OPERATING CASH FLOW
-9.20%
-309 K INVESTING CASH FLOW
27.09%
7.34 M FINANCING CASH FLOW
362.59%
583 K REVENUE
190.61%
-1.76 M OPERATING INCOME
19.08%
-1.76 M NET INCOME
19.23%
-961 K OPERATING CASH FLOW
39.93%
-23.6 K INVESTING CASH FLOW
-590.99%
888 K FINANCING CASH FLOW
-48.33%
Balance Sheet PetVivo Holdings, Inc.
image
Current Assets 1.04 M
Cash & Short-Term Investments 87.4 K
Receivables 18.7 K
Other Current Assets 936 K
Non-Current Assets 2.07 M
Long-Term Investments 0
PP&E 2.02 M
Other Non-Current Assets 57.6 K
Current Liabilities 1.41 M
Accounts Payable 821 K
Short-Term Debt 348 K
Other Current Liabilities 243 K
Non-Current Liabilities 1.02 M
Long-Term Debt 1.02 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall PetVivo Holdings, Inc.
image
Revenue 969 K
Cost Of Revenue 229 K
Gross Profit 740 K
Operating Expenses 11.4 M
Operating Income -10.6 M
Other Expenses 334 K
Net Income -11 M
RATIOS
76.34% GROSS MARGIN
76.34%
-1096.45% OPERATING MARGIN
-1096.45%
-1130.92% NET MARGIN
-1130.92%
-1597.09% ROE
-1597.09%
-351.67% ROA
-351.67%
-517.86% ROIC
-517.86%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PetVivo Holdings, Inc.
image
Net Income -11 M
Depreciation & Amortization 127 K
Capital Expenditures -309 K
Stock-Based Compensation 2.63 M
Change in Working Capital 172 K
Others 648 K
Free Cash Flow -7.73 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PetVivo Holdings, Inc.
image
PETV has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership PetVivo Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
90 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
10 months ago
Apr 15, 2024
Bought 90 K USD
Lai John
CEO and President
+ 150000
0.6 USD
1 year ago
Aug 21, 2023
Bought 9.91 K USD
Martin James Rudolph
Director
+ 4482
2.21 USD
1 year ago
Aug 21, 2023
Bought 654 USD
Martin James Rudolph
Director
+ 300
2.18 USD
1 year ago
Aug 21, 2023
Bought 480 USD
Martin James Rudolph
Director
+ 218
2.2 USD
1 year ago
Aug 21, 2023
Bought 4.24 K USD
Martin James Rudolph
Director
+ 1850
2.29 USD
1 year ago
Aug 21, 2023
Bought 17.2 K USD
Martin James Rudolph
Director
+ 7300
2.35 USD
1 year ago
Aug 21, 2023
Bought 1.93 K USD
Martin James Rudolph
Director
+ 850
2.27 USD
1 year ago
Aug 21, 2023
Bought 464 USD
Martin James Rudolph
Director
+ 200
2.32 USD
1 year ago
Aug 21, 2023
Bought 51.6 USD
Martin James Rudolph
Director
+ 24
2.15 USD
1 year ago
Aug 21, 2023
Bought 6.06 K USD
Martin James Rudolph
Director
+ 2600
2.33 USD
1 year ago
Aug 21, 2023
Bought 2.24 K USD
Martin James Rudolph
Director
+ 1000
2.24 USD
1 year ago
Aug 21, 2023
Bought 4.79 K USD
Martin James Rudolph
Director
+ 2100
2.28 USD
1 year ago
Aug 21, 2023
Bought 3.04 K USD
Martin James Rudolph
Director
+ 1300
2.34 USD
1 year ago
Mar 15, 2023
Bought 1.06 K USD
Costantino Robert J
Director
+ 350
3.035 USD
1 year ago
Mar 15, 2023
Bought 3.03 K USD
Costantino Robert J
Director
+ 1000
3.03 USD
1 year ago
Mar 15, 2023
Bought 6.04 K USD
Costantino Robert J
Director
+ 2000
3.02 USD
1 year ago
Mar 13, 2023
Bought 6.2 K USD
Jasper Joseph William
Director
+ 2000
3.1 USD
2 years ago
Mar 01, 2023
Bought 1.47 K USD
Jasper Joseph William
Director
+ 500
2.94 USD
2 years ago
Feb 28, 2023
Bought 1.56 K USD
Jasper Joseph William
Director
+ 501
3.12 USD
2 years ago
Feb 27, 2023
Bought 2.98 K USD
Jasper Joseph William
Director
+ 1000
2.98 USD
2 years ago
Feb 27, 2023
Bought 1.17 K USD
Jasper Joseph William
Director
+ 399
2.93 USD
2 years ago
Feb 24, 2023
Bought 1.78 K USD
Jasper Joseph William
Director
+ 600
2.96 USD
2 years ago
Feb 24, 2023
Bought 5.96 K USD
Jasper Joseph William
Director
+ 2000
2.98 USD
2 years ago
Feb 21, 2023
Bought 2.09 K USD
Martin James Rudolph
Director
+ 700
2.98 USD
2 years ago
Feb 21, 2023
Bought 299 USD
Martin James Rudolph
Director
+ 100
2.99 USD
2 years ago
Feb 21, 2023
Bought 7.5 K USD
Martin James Rudolph
Director
+ 2500
3 USD
2 years ago
Feb 16, 2023
Bought 308 USD
Martin James Rudolph
Director
+ 103
2.99 USD
2 years ago
Feb 15, 2023
Bought 1.18 K USD
Martin James Rudolph
Director
+ 400
2.95 USD
2 years ago
Feb 15, 2023
Bought 20.9 K USD
Martin James Rudolph
Director
+ 7900
2.64 USD
2 years ago
Feb 15, 2023
Bought 255 USD
Martin James Rudolph
Director
+ 100
2.55 USD
2 years ago
Feb 14, 2023
Bought 253 USD
Martin James Rudolph
Director
+ 99
2.56 USD
2 years ago
Feb 14, 2023
Bought 813 USD
Martin James Rudolph
Director
+ 300
2.71 USD
2 years ago
Feb 14, 2023
Bought 10.3 K USD
Martin James Rudolph
Director
+ 4000
2.57 USD
2 years ago
Feb 14, 2023
Bought 8.89 K USD
Martin James Rudolph
Director
+ 3500
2.54 USD
2 years ago
Nov 22, 2022
Bought 2.5 K USD
Lai John
CEO and President
+ 1000
2.5 USD
2 years ago
Nov 21, 2022
Bought 2.28 K USD
Rudelius Robert James
Director
+ 860
2.65 USD
2 years ago
Nov 21, 2022
Bought 2.55 K USD
Lai John
CEO and President
+ 1000
2.55 USD
2 years ago
Nov 18, 2022
Bought 1.04 K USD
Rudelius Robert James
Director
+ 400
2.6 USD
2 years ago
Nov 18, 2022
Bought 3.16 K USD
Rudelius Robert James
Director
+ 1240
2.55 USD
2 years ago
Nov 18, 2022
Bought 2.11 K USD
Lai John
CEO and President
+ 807
2.61 USD
2 years ago
Nov 18, 2022
Bought 779 USD
Lai John
CEO and President
+ 303
2.57 USD
2 years ago
Nov 17, 2022
Bought 2.6 K USD
Lai John
CEO and President
+ 1066
2.4399 USD
2 years ago
Nov 17, 2022
Bought 1.98 K USD
Lai John
CEO and President
+ 790
2.51 USD
2 years ago
Nov 16, 2022
Bought 86.4 USD
Lai John
CEO and President
+ 34
2.54 USD
2 years ago
Nov 16, 2022
Bought 2.44 K USD
Lai John
CEO and President
+ 1000
2.4399 USD
2 years ago
Nov 16, 2022
Bought 2.44 K USD
Lai John
CEO and President
+ 1000
2.44 USD
2 years ago
Nov 15, 2022
Bought 2.38 K USD
Lai John
CEO and President
+ 1006
2.37 USD
2 years ago
Nov 15, 2022
Bought 4.69 K USD
Lai John
CEO and President
+ 1994
2.35 USD
2 years ago
Aug 16, 2022
Bought 583 USD
Costantino Robert J
director:
+ 234
2.49 USD
2 years ago
Aug 16, 2022
Bought 1.43 K USD
Martin James Rudolph
director:
+ 578
2.47 USD
2 years ago
Aug 16, 2022
Bought 51.7 USD
Martin James Rudolph
Director
+ 22
2.35 USD
2 years ago
Aug 16, 2022
Bought 6.12 K USD
Martin James Rudolph
Director
+ 2500
2.45 USD
2 years ago
Aug 16, 2022
Bought 1.42 K USD
Martin James Rudolph
Director
+ 600
2.36 USD
2 years ago
Aug 16, 2022
Bought 708 USD
Martin James Rudolph
Director
+ 300
2.36 USD
2 years ago
Jul 01, 2022
Bought 1.35 K USD
Lai John
CEO
+ 779
1.734 USD
2 years ago
Jul 01, 2022
Bought 4.44 K USD
Lai John
CEO
+ 2544
1.745 USD
2 years ago
Jul 01, 2022
Bought 12 K USD
Lai John
CEO
+ 6677
1.79 USD
3 years ago
Feb 28, 2022
Bought 11.4 K USD
Martin James Rudolph
Director
+ 7500
1.5191 USD
3 years ago
Aug 13, 2021
Bought 18 K USD
Johnson Scott Mitchell
Director
+ 4000
4.5 USD
3 years ago
May 04, 2021
Sell 885 USD
Johnson Scott Mitchell
Director
- 100
8.85 USD
3 years ago
May 04, 2021
Sell 783 USD
Johnson Scott Mitchell
Director
- 90
8.7 USD
3 years ago
May 05, 2021
Sell 16.4 K USD
Johnson Scott Mitchell
Director
- 2115
7.75 USD
3 years ago
May 10, 2021
Sell 2.3 K USD
Johnson Scott Mitchell
Director
- 271
8.5 USD
3 years ago
May 10, 2021
Sell 8.12 K USD
Johnson Scott Mitchell
Director
- 950
8.55 USD
3 years ago
Aug 13, 2021
Bought 22.5 K USD
Johnson Scott Mitchell
Director
+ 4000
5.625 USD
3 years ago
Oct 05, 2021
Bought 1.47 K USD
Martin James Rudolph
Director
+ 600
2.4499 USD
3 years ago
Oct 05, 2021
Bought 1.23 K USD
Martin James Rudolph
Director
+ 500
2.4645 USD
3 years ago
Oct 05, 2021
Bought 1.24 K USD
Martin James Rudolph
Director
+ 500
2.47 USD
3 years ago
Sep 14, 2021
Bought 3.55 K USD
Martin James Rudolph
Director
+ 1200
2.96 USD
3 years ago
Sep 13, 2021
Bought 3.24 K USD
Martin James Rudolph
Director
+ 1000
3.24 USD
3 years ago
Sep 13, 2021
Bought 1.58 K USD
Martin James Rudolph
Director
+ 500
3.17 USD
3 years ago
Sep 13, 2021
Bought 4.8 K USD
Martin James Rudolph
Director
+ 1500
3.2 USD
3 years ago
Sep 13, 2021
Bought 6.5 K USD
Martin James Rudolph
Director
+ 2000
3.25 USD
3 years ago
Sep 13, 2021
Bought 6.54 K USD
Martin James Rudolph
Director
+ 2000
3.2699 USD
3 years ago
Sep 02, 2021
Bought 8.48 K USD
Folkes Robert J.
Chief Financial Officer
+ 2147
3.95 USD
3 years ago
Sep 02, 2021
Bought 7.26 K USD
Folkes Robert J.
Chief Financial Officer
+ 1843
3.94 USD
3 years ago
Sep 02, 2021
Bought 393 USD
Folkes Robert J.
Chief Financial Officer
+ 100
3.93 USD
3 years ago
Sep 02, 2021
Bought 39 USD
Folkes Robert J.
Chief Financial Officer
+ 10
3.9 USD
3 years ago
Sep 02, 2021
Bought 22.9 K USD
Folkes Robert J.
Chief Financial Officer
+ 5895
3.89 USD
3 years ago
Sep 02, 2021
Bought 18.7 USD
Folkes Robert J.
Chief Financial Officer
+ 5
3.74 USD
3 years ago
Aug 25, 2021
Bought 1.83 K USD
Martin James Rudolph
Director
+ 700
2.6092 USD
3 years ago
Aug 25, 2021
Bought 3.51 K USD
Martin James Rudolph
Director
+ 1300
2.7 USD
3 years ago
Aug 11, 2021
Bought 11.2 K USD
Martin James Rudolph
Director
+ 2500
4.49 USD
3 years ago
Aug 11, 2021
Bought 17.4 K USD
Martin James Rudolph
Director
+ 5000
3.4848 USD
3 years ago
Jun 02, 2021
Bought 5.6 K USD
Deming David Don
Director
+ 800
7 USD
3 years ago
May 28, 2021
Bought 21 K USD
Folkes Robert J.
CFO
+ 3000
7 USD
3 years ago
Apr 24, 2021
Bought 21 K USD
Martin James Joseph
Director
+ 3000
7 USD
4 years ago
May 14, 2020
Bought 5.08 K USD
CASH GREGORY D
Director
+ 20002
0.2538 USD
4 years ago
May 14, 2020
Bought 10.2 K USD
Martin James Rudolph
Director
+ 40004
0.2538 USD
4 years ago
Jul 16, 2020
Bought 4 K USD
Johnson Scott Mitchell
Director
+ 5000
0.8 USD
4 years ago
Jul 13, 2020
Bought 2.7 K USD
Martin James Rudolph
Director
+ 3000
0.9 USD
4 years ago
Jul 09, 2020
Bought 712 USD
Johnson Scott Mitchell
Director
+ 925
0.77 USD
4 years ago
Jul 08, 2020
Bought 3.38 K USD
Johnson Scott Mitchell
Director
+ 4070
0.83 USD
4 years ago
Jul 09, 2020
Bought 813 USD
Martin James Rudolph
Director
+ 1000
0.8134 USD
4 years ago
Jul 08, 2020
Bought 2.23 K USD
Martin James Rudolph
Director
+ 2400
0.93 USD
4 years ago
Jul 06, 2020
Bought 2.9 K USD
Martin James Rudolph
Director
+ 4684
0.62 USD
4 years ago
Jul 06, 2020
Bought 1.72 K USD
Martin James Rudolph
Director
+ 3300
0.52 USD
4 years ago
Jul 06, 2020
Bought 3 K USD
Martin James Rudolph
Director
+ 6000
0.5 USD
4 years ago
Jul 02, 2020
Bought 1.84 K USD
Martin James Rudolph
Director
+ 4000
0.46 USD
4 years ago
Jul 02, 2020
Bought 490 USD
Martin James Rudolph
Director
+ 1090
0.45 USD
4 years ago
Jul 02, 2020
Bought 2.29 K USD
Martin James Rudolph
Director
+ 5210
0.44 USD
4 years ago
Jun 30, 2020
Bought 1.22 K USD
Martin James Rudolph
Director
+ 2766
0.44 USD
4 years ago
Jun 30, 2020
Bought 1.23 K USD
Martin James Rudolph
Director
+ 3067
0.4 USD
4 years ago
Jun 30, 2020
Bought 1.05 K USD
Martin James Rudolph
Director
+ 2667
0.395 USD
4 years ago
Jun 30, 2020
Bought 982 USD
Martin James Rudolph
Director
+ 2500
0.393 USD
4 years ago
May 14, 2020
Bought 10 K USD
Martin James Rudolph
Director
+ 39401
0.2538 USD
4 years ago
Jun 08, 2020
Bought 2.96 K USD
Martin James Rudolph
Director
+ 8000
0.37 USD
4 years ago
Jun 05, 2020
Bought 2.13 K USD
Martin James Rudolph
Director
+ 5750
0.37 USD
4 years ago
Jun 01, 2020
Bought 1 K USD
Martin James Rudolph
Director
+ 3030
0.33 USD
4 years ago
May 29, 2020
Bought 675 USD
Martin James Rudolph
Director
+ 2500
0.27 USD
4 years ago
May 29, 2020
Bought 2.1 K USD
Martin James Rudolph
Director
+ 7500
0.28 USD
5 years ago
Nov 29, 2019
Bought 1 K USD
Martin James Rudolph
Director
+ 2500
0.4 USD
5 years ago
Nov 14, 2019
Bought 4 K USD
Martin James Rudolph
Director
+ 10000
0.4 USD
5 years ago
Nov 04, 2019
Bought 1.02 K USD
Martin James Rudolph
Director
+ 2500
0.41 USD
5 years ago
Oct 03, 2019
Bought 988 USD
Martin James Rudolph
Director
+ 2500
0.395 USD
5 years ago
Sep 03, 2019
Bought 1.44 K USD
Martin James Rudolph
Director
+ 4250
0.34 USD
5 years ago
Sep 03, 2019
Bought 1.44 K USD
Martin James Rudolph
Director
+ 4250
0.34 USD
5 years ago
Sep 03, 2019
Bought 1.5 K USD
Martin James Rudolph
Director
+ 5000
0.3 USD
7 years ago
Mar 01, 2018
Bought 1.81 K USD
Deming David Don
Director
+ 1000
1.81 USD
10 years ago
Aug 14, 2014
Bought 16 K USD
Dolan John F.
CFO
+ 2666667
0.006 USD
10 years ago
Aug 14, 2014
Bought 24 K USD
Lai John
President
+ 4000000
0.006 USD
10 years ago
Apr 01, 2014
Bought 48 K USD
Lai John
CEO
+ 3200000
0.015 USD
7. News
Petvivo Holdings, Inc. to Exhibit at the Western Veterinary Conference in Las Vegas, Nevada MINNEAPOLIS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held March 2nd to March 5th, 2025 at the Mandalay Bay Convention Center in Las Vegas, Nevada. globenewswire.com - 1 week ago
PetVivo Reports Fiscal Q3 2025 Results MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for equines and companion animals, reported results for its fiscal third quarter ended December 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. globenewswire.com - 2 weeks ago
PetVivo Signs Exclusive Sales and Marketing Agreement with VetStem for PrecisePRP® Canine and Equine Products MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize VetStem's innovative allogeneic orthobiologic products, PrecisePRP® canine and PrecisePRP® equine. PrecisePRP® is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. globenewswire.com - 2 weeks ago
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024 MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and OTCPINK: PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Friday, February 14, 2025 after market close. The company will host a conference call to discuss these results at 2:00 p.m. CT (3:00 p.m. ET) on the same day. globenewswire.com - 2 weeks ago
PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor PetVivo Board Appoints Eldred as Executive Director to Lead Company  Product Commercialization and Operations globenewswire.com - 1 month ago
PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the Veterinary Meeting and Expo Conference in Orlando, Florida on January 25-29, 2025 MINNEAPOLIS, MN, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals today announced it will be exhibiting at the Veterinary Meeting & Expo Conference to held from January 25th to January 29th, 2025, at the Orange County Convention Center, Exhibit Halls B, C and D, in Orlando, Florida. globenewswire.com - 1 month ago
PETVIVO HOLDING, INC. ANNOUNCES PARTNERSHIP ENGAGEMENTS WITH VEDCO, INC. MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo"), a pioneering biomedical technology company focused on adapting human biotech, medical device and other therapeutic technologies into osteoarthritis and lameness products for commercial sale in the US companion animal and equine markets, announces new distribution partnerships with Vedco Inc. (“Vedco”), and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products to veterinarians through the channel-of-distribution for veterinarians. Vedco and Clipper distribute to many of the largest national veterinary product distribution entities in the United States, including MWI, Covetrus, Patterson, Midwest Supply and Penn Supply, to just name a few. globenewswire.com - 1 month ago
PETVIVO HOLDINGS, INC. TO HOST SHAREHOLDERS UPDATE MEETING ON JANUARY 8, 2025 MINNEAPOLIS, MN, US, Dec. 30, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will host a live webcast Shareholders Update Meeting to provide an overview of the Company's progress in the 2025 fiscal year and a look into the potential future of the Company. The Shareholders Update Meeting: 2025 Company Overview will be held on Wednesday, January 8, 2025 at 3:30 p.m. CT (4:30 p.m. ET). globenewswire.com - 2 months ago
PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025 MINNEAPOLIS, MN / ACCESSWIRE / December 19, 2024 / PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. accesswire.com - 2 months ago
PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the American Association of Equine Practitioners Convention on December 8-10, 2024 MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will exhibit at the American Association of Equine Practitioners (“AAEP”) convention to be held December 8th to December 10th, 2024 at the Orange County Convention Center, Exhibit Halls B, C and D, in Orlando, Florida. globenewswire.com - 3 months ago
PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript PetVivo Holdings, Inc. (OTCPK:PETV) Q2 2025 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer Garry Lowenthal - Chief Financial Officer Conference Call Participants John Dolan Good afternoon, everyone. Thank you for joining us today to discuss PetVivo's Results for its Fiscal Second Quarter ended September 30, 2024. seekingalpha.com - 3 months ago
PetVivo Reports Fiscal Q2 2025 Results MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. globenewswire.com - 3 months ago
8. Profile Summary

PetVivo Holdings, Inc. PETV

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 12 M
Dividend Yield 0.00%
Description PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Contact 5251 Edina Industrial Boulevard, Minneapolis, MN, 55439 https://www.petvivo.com
IPO Date Sept. 8, 2014
Employees 20
Officers Mr. John F. Dolan General Counsel, Chief Business Development Officer & Secretary Mr. Gary DeMel Executive Vice President of Business Development Ms. April Boyce Vice President of Sales & Marketing Mr. Randy Wenthold Chief Science Officer Mr. Garry N. Lowenthal Chief Financial Officer Mr. John Lai Chief Executive Officer, President & Director Mr. Michael Eldred BA, MBA Commercialization & Operations Advisor and Executive Director